Morgan Stanley analyst Lisa De Neve lowered the firm’s price target on IFF (IFF) to $98 from $100 and keeps an Overweight rating on the shares. IFF offers a diversified customer and regional footprint, innovation launches and tailwinds from a meaningful regulatory wave driving reformulation, driving about three times the rate of U.S. Consumer Staples growth over FY25-26, the analyst tells investors. The firm has adjusted its model for the completed Pharma Divestment and lower projected net interest costs, leaving its FY25, FY26 and FY27 adjusted EPS forecasts 1.8%, 4.8% and 6.1% lower, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFF:
- Strong Growth Potential and Attractive Valuation Make International Flavors & Fragrances a Compelling Investment
- Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls
- IFF price target lowered to $100 from $110 at Baird
- IFF price target raised to $90 from $84 at Citi
- IFF upgraded to Overweight from Equal Weight at Barclays